TP53 and colorectal carcinoma: Specifically, it appears that inhibition of CHK1, but not CHK2, caused a greater abrogation of the G2 phase by DNA-damaging treatments and a greater sensibility to the same treatments in CRC cells characterized with TP53 and p21 wild-type proteins [518].